Pharma, Healthcare Q2 Results Preview - Double-Digit Growth Led By New Launches: Axis Securities

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Axis Securities Report.Pharma:We anticipate that the pharmaceutical companies within our coverage will collectively demonstrate revenue growth of 8.5% YoY and 3.1% QoQ, along with Ebitda growth of 10.5% YoY and 3.8% QoQ. Moreover, adjusted PAT is expected to grow by 14% YoY and 1% QoQ. This growth will likely be driven by domestic formulations and niche launches in the U.S. market.In U.S. generics, growth is particularly driven by products such as gRevlimid, gMirabegron, gSpiriva, gAlbuterol, gPrezista, gLenalidomide, gProlensa, gChantix, and various biosimilars. The U.S. market is anticipated to witness low single-digit growth, led by volume growth in existing products and the launch of new products in the last quarter like gMirabegron, despite elevated pricing erosion. Meanwhile, the Indian business is expected to experience a comeback compared to the last quarter, driven by robust growth in chronic therapies and a recovery in acute therapies. We estimate that Dr. Reddy's, Cipla, and Aurobindo will report gRevlimid sales of $125 million, $30 million, and $30 million, respectively, for Q2 FY25E..Healthcare: In our coverage, we anticipate that the healthcare sector will register revenue growth of 9.4% YoY and 4.5% QoQ, largely driven by an anticipated improvement in occupancies of up to 200 basis points and average revenue per occupied bed growth of 5-6%. Our analysis indicates that KIMS and Healthcare Global could achieve growth of 12% on a YoY basis. However, Medanta may lag behind its peers due to sluggish development at the Lucknow facility, where occupancies have declined from their peak levels due to the absence of seasonality or acute cases as seen last year. We anticipate a 10% loss in occupancies in the Lucknow unit as a result. Overall, we expect moderate revenue growth of 5% YoY, supported by the mature hospital in Gurgaon. Additionally, we project an adjusted Ebitda growth of 10.8% YoY and 7.4% QoQ for our hospital coverage..Click on the attachment to read the full report:.Capital Goods Q2 Results Preview - Momentum Picking Up Pace Selectively: Motilal Oswal.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Pharma, Healthcare Q2 Results Preview - Double-Digit Growth Led By New Launches: Axis Securities

The brokerage recommends Buy on Lupin, Aurobindo, Abbott India, HCG, and KIMS, know why?

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Pharma, Healthcare Q2 Results Preview - Double-Digit Growth Led By New Launches: Axis Securities

The brokerage recommends Buy on Lupin, Aurobindo, Abbott India, HCG, and KIMS, know why?

Choose a plan

Follow Us

DOWNLOAD THE APP